Study of Pasireotide LAR and Pegvisomant Treatments for Bone Health in Adults with Acromegaly Not Controlled by First-Generation Somatostatin Receptor Ligands

What this Trial Is About

Acromegaly is a chronic condition marked by excess growth hormone and insulin-like growth factor-1, leading to systemic and metabolic problems that reduce quality of life and life expectancy. A specific bone disease related to acromegaly causes fragile fractures, especially vertebral fractures, which are common and linked to pain and reduced quality of life. This research compares the effects of two treatments, Pasireotide LAR and Pegvisomant, on bone health in patients with acromegaly who did not respond adequately to first-generation somatostatin receptor ligands fg-SRLs. The study includes two groups a prospective cohort of patients switched to Pasireotide LAR and a retrospective cohort switched to Pegvisomant after fg-SRLs therapy, reflecting usual clinical practice. Patients continue their treatments as prescribed, and their bone health is assessed through morphometric spine radiography and bone density scans of the lumbar spine and femur. Follow-up evaluations occur over one year to monitor changes. Participants are adults with acromegaly not controlled after six months of fg-SRLs treatment and must have switched to either Pasireotide LAR or Pegvisomant. They undergo imaging tests to assess bone fractures and density, with researchers comparing outcomes over 36 months. The study collects data on bone health, treatment effects, and safety during this period, aiming to better understand how these therapies affect skeletal fragility in acromegaly.

Effects of Pasireotide Lar Therapy on Bone Metabolism